Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Sponsor: Radius Health, Inc.
Listed as NCT04064411, this PHASE3 trial focuses on Postmenopausal Osteoporosis and remains completed. Sponsored by Radius Health, Inc., it has been updated 14 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Mar 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
May 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Radius Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .